Lactoferrin benefits for women: what the research shows, and what brands can build with it

Iron deficiency fatigue in women: a problem the standard supplement hasn't solved

Close to 30% of non-pregnant women of reproductive age are anemic worldwide, rising to more than 36% in pregnancy (Christofi et al., 2024). Iron deficiency is the most common single-nutrient deficiency on the planet, its prevalence highest in women of childbearing age (Nappi et al., 2009), and fatigue is its leading symptom (Zhao et al., 2022). The diagnosed cases are only part of it. Iron status declines along a spectrum, from depletion that produces no measurable physiological impairment through to iron-deficiency anemia (Nappi et al., 2009) which means a large population feels the effects without ever meeting a diagnostic threshold, obtaining a supplement, and not a prescription.

And the supplement aisle has a problem. Ferrous sulfate, the conventional answer, carries a tolerability burden that drives people off it. Ferrous bisglycinate, the category's premium response, is a genuine improvement but it works on the same half of the problem: how comfortably iron gets in, rather than what the body does with it once it's there. For a large share of women, the deficit sits in that second step. Which is why the category keeps refining the same answer and keeps hitting the same ceiling.

Why the standard iron supplement falls short

Conventional oral iron preparations such as ferrous sulfate can be associated with gastrointestinal side effects, which may affect tolerability and adherence (Tolkien et al., 2015). Fractional iron absorption (the proportion of ingested iron that actually enters circulation) amounts to only 10 to 20% or less after oral intake. That means 80 to 90% of ingested iron stays in the gut lumen, where it generates free radicals that irritate and inflame the gut wall (Nappi et al., 2009). Roughly 40% of iron supplement consumers experience digestive discomfort as a result.

Absorption is also easily disrupted by everyday diet. Non-heme iron, the form used in most oral supplements, including ferrous sulfate, fumarate and gluconate, is only moderately bioavailable, at around 20 to 30% (Artym et al., 2021). From food, the numbers are lower still: non-heme iron in vegetables and cereals is absorbed at rates as low as 2 to 5%, and 15 to 25% for heme iron from animal sources (Koikawa et al., 2008). Because several minerals compete for the same absorption pathways, common guidance is to take iron between meals or to take it fast, and to avoid combined multimineral products, since calcium, copper, zinc, manganese and iron mutually restrict one another's uptake (Artym et al., 2021).

For the consumer, that guidance is a daily scheduling problem. An iron supplement that has to be taken on an empty stomach, apart from a meal and coffee, and separately from a multivitamin or calcium supplement is difficult to fit around work, training schedules, or simply a full calendar. The regimens most likely to be abandoned are the ones that ask the most of the routine. Combined with the gastrointestinal burden, this is why the category's compliance problem is not solved by better iron chemistry alone. Consumers are still looking for gentler, more efficient ways to supplement and improve iron status.

In a randomized controlled trial comparing lactoferrin with ferrous sulfate in pregnant women, constipation occurred in 92% of the ferrous sulfate group versus 14% of the lactoferrin group. Gastric upset affected 84% of the ferrous sulfate group and 30% of the lactoferrin group. Overall patient acceptability was 22% for ferrous sulfate and96% for lactoferrin (Gawai et al., 2020). Two patients in another trial discontinued ferrous sulfate entirely because of severe constipation; no patients in the lactoferrin group stopped for this reason (Nappi et al., 2009).

Poor tolerability translates directly into poor adherence. A supplement that sits in a drawer does not improve anyone's iron status.

What about ferrous bisglycinate?

The category has already responded to the tolerability problem by premiumizing into gentler chelated forms, ferrous bisglycinate being the most relevant, marketed on better absorption and easier digestion. It is a real improvement on ferrous sulfate, and it has earned its position.

But it is still a simple iron salt, and it is still working on the same half of the problem. Chelated forms address how comfortably iron gets in. They do not address what happens to iron once it is in the body and for a significant share of women, that second step is where the deficit actually sits.

So why doesn't more iron fix it? Or better-absorbed iron?

Because for a meaningful share of women, the iron isn't missing. It's stranded, and the thing stranding it is inflammation. That inflammation has ordinary sources: chronic infection or an ongoing inflammatory condition, metabolic endotoxemia (the low-grade inflammatory state associated with metabolic syndrome), chronic gut inflammation, celiac disease, Helicobacter pylori infection, or regular NSAID use - all of which disturb iron absorption in their own right (Artym et al., 2021). And, with a certain irony, the iron supplement itself drives inflammation: because only 20 to 30% of an oral ferrous salt dose is absorbed, the unabsorbed majority passes into the gut lumen, where it can promote oxidative stress, subclinical inflammation and an unfavourable shift in the gut microbiome (Artym et al., 2021).

Whatever the source, the downstream step is the same, and it runs through hepcidin. This hormone binds to ferroportin, the only known cellular exporter of iron into the bloodstream, and triggers its internalisation and degradation, blocking both the release of iron from the gut into circulation and the release of iron held in liver and macrophage stores (Artym et al., 2021; Zhao et al., 2022). Hepcidin synthesis is driven by interleukin-6 (IL-6), so where inflammation is elevated, hepcidin rises, ferroportin is degraded, and iron release into plasma is impaired regardless of how much iron the person is taking (Christofi et al., 2024). Iron ends up locked in the cells that store it.

No iron salt, however well tolerated, changes this. Hepcidin regulation is a systemic step that sits downstream of absorption, which is why increasing the dose or improving the chelate does not have an impact.

This is the limitation of iron salts and the opportunity commercially. Unlike conventional iron supplements that include premium forms such as ferrous bisglycinate, lactoferrin may also support a healthier intestinal and inflammatory environment which is relevant precisely because chronic inflammation can interfere with normal iron absorption and mobilization.

What lactoferrin does differently: the mechanism

Lactoferrin is a glycoprotein (a protein with sugar chains attached) from the transferrin family and is naturally present in human and bovine milk. Its most relevant property for iron support is its iron-binding affinity. Unlike transferrin, it can sequester iron at broader pH ranges and physiological conditions (Artym et al., 2021).

Rather than dumping free iron into the gut lumen, lactoferrin binds iron tightly and delivers it via receptor-mediated endocytosis: intestinal cells take up the lactoferrin-iron complex intact, iron is released inside the cell, and transferrin then carries it into circulation (Nappi et al., 2009).

It is worth noting that even when fully loaded with iron, lactoferrin contains only approximately 0.14% iron by weight. Lactoferrin is not acting primarily as an iron source. Its value lies in how iron is mobilized and used, not in how much it carries.

The anti-inflammatory angle: hepcidin and IL-6

Not all iron-related fatigue has the same cause. In some women, the shortfall is dietary: too little iron is coming in. In others, iron intake is adequate and the stores are there, but chronic inflammation is preventing the body from reaching them. These two situations look similar from the outside but respond very differently to supplementation.

Lactoferrin works directly on inflammation. By lowering inflammatory signals, IL-6, it reduces hepcidin production, and with less hepcidin present, ferroportin remains intact on the cell surface and iron can be released into circulation rather than held in storage (Artym et al. 2021; Christofi et al. 2024). Iron salts do not act on this step. Inorganic iron formulas like sulfate, fumarate and gluconate, have been reported either not to affect the inflammatory state or, in some cases, to intensify it, which in turn further disrupts iron homeostasis (Artym et al., 2021). The proposed route is the unabsorbed fraction: with only around 20 to 30% of an oral ferrous salt dose absorbed, the majority passes through the gut lumen, where it can promote oxidative stress, chronic inflammation and an undesirable shift in the gut microbiome profile (Artym et al., 2021; Abu Hashim et al., 2017).

The question R&D teams always ask: if lactoferrin delivers a fraction of the iron, why do the markers improve?

This is a fair objection that comes up in every technical conversation. A therapeutic dose of ferrous sulfate supplies 100 to 200 mg of elemental iron (Abu Hashim et al., 2017). A 100 to 250 mg dose of bovine lactoferrin carries in the region of 8 to 80 µg of iron (Artym et al., 2021), a difference of several orders of magnitude. Zhao et al. (2022) also found fractional iron absorption to be lower with lactoferrin than with ferrous sulfate. On a simple input basis, lactoferrin should not be able to compete.

Two things are worth saying about that absorption finding. The first is that it rests on limited data: it was drawn from only two of the eight studies in the meta-analysis, with small participant numbers, and the authors state the comparison should be interpreted cautiously (Zhao et al., 2022). The second is that it does not weaken the case for lactoferrin. The endpoints that matter clinically came from the fuller dataset, and on those, lactoferrin performed better.

The same meta-analysis found significantly higher serum iron with lactoferrin than with ferrous sulfate (weighted mean difference +41.44 µg/dL), significantly higher serum ferritin (+13.6 ng/mL), and a significant advantage in hemoglobin (Zhao et al., 2022). The proposed explanation is the anti-inflammatory mechanism described above: by reducing IL-6 and hepcidin, lactoferrin allows the body to mobilize and use iron already held in storage.

Iron salts work on supply by flooding the gut and accepting that most of the dose is never absorbed. Lactoferrin works on regulation. The story is not about how much iron an ingredient delivers, but about whether the body can access it, and that is a differentiated, defensible position to build a product on.

The evidence: better iron markers without the tolerability trade-off

The clinical evidence spans multiple randomized controlled trials. Across all of them, the pattern is consistent: lactoferrin produces equivalent or superior improvements in key iron-status markers compared to ferrous sulfate, at doses that carry substantially less gastrointestinal burden.

• In the Nappi et al. (2009) double-blind RCT (100 pregnant women, 30 days), bovine lactoferrin at 100 mg twice daily produced statistically equivalent improvements in hemoglobin, serum ferritin, serum iron, and total iron-binding capacity (TIBC) compared to a 100 mg of elemental iron, with significantly fewer gastrointestinal side effects.
• In the Gawai et al. (2020) RCT (100 pregnant women, 8 weeks), lactoferrin at 250 mg twice daily produced a hemoglobin rise of 1.58 g/dL versus 1.67 g/dL for ferrous sulfate. Serum iron rose by more in the lactoferrin group (39.90 µg/dL versus 37.21 µg/dL). The hematological outcomes were comparable; the tolerability outcomes were not.
• The Abu Hashim et al. (2017) meta-analysis of four RCTs covering 600 pregnant women found pooled estimates for hemoglobin change at four weeks favored lactoferrin over ferrous sulfate (mean difference 0.77 g/dL; 95% CI 0.04 to 1.55; p = 0.04). On tolerability, the pooled odds of epigastric discomfort with lactoferrin were roughly a tenth of those with ferrous sulfate (OR 0.11; 95% CI 0.05 to 0.22; p < 0.00001), with constipation at around a fifth (OR 0.22; 95% CI 0.12 to 0.40; p < 0.00001) and vomiting at around a third (OR 0.32; 95% CI 0.15 to 0.67; p = 0.002). The authors rated this evidence moderate quality.
• The Artym et al. (2021) comprehensive review, synthesizing data from trials monitoring 3,367 pregnant women, concluded that oral bovine lactoferrin at daily doses of 25 to 250 mg was comparable to, or greater in efficacy than, inorganic iron sulfate delivering 156 mg of elemental iron, while reducing chronic inflammation and GI side effects.

Bovine lactoferrin at 100 to 250 mg per day delivers only approximately 8 to 80 µg of elemental iron. Ferrous sulfate at therapeutic doses delivers 100 to 200 mg of elemental iron. The clinical outcomes are comparable or better with a fraction of the iron load, because the mechanism of action is fundamentally different.

Translating the science into product development, positioning and claims: smarter iron supplementation

Lactoferrin benefits for women, and how to communicate them

The published evidence points to several territories in which products containing Vivitein™ LF can be positioned. What is claimable in any given market will depend on the jurisdiction, the format and the dose, and remains a matter for the brand's regulatory affairs team, but the research indicates where the credible product stories sit:

• Gentle iron supplement: Significantly lower rates of constipation, gastric upset, vomiting, and dark stools compared to ferrous sulfate are documented across multiple randomized controlled trials. The mechanism (receptor-mediated delivery, no free iron release into the gut lumen) is well described (Nappi et al., 2009).
• Supporting healthy iron status: Improvements in serum iron, serum ferritin, and hemoglobin are documented across the trial base, with a large meta-analysis confirming superior outcomes versus ferrous sulfate (Zhao et al., 2022). The framing should focus on iron regulation and mobilization rather than direct iron delivery.
• Unlock iron already in the body: Many women are not short of iron so much as unable to reach it: chronic inflammation drives hepcidin production, ferroportin is degraded, and iron stays held in storage (Christofi et al., 2024). Lactoferrin acts on this step rather than on intake alone (Artym et al., 2021), which is why it can improve iron markers while delivering a fraction of the iron, and why no iron salt occupies this territory.
• Sustained energy: Iron status underpins hemoglobin synthesis, oxygen transport and cellular energy production, and fatigue is a recognized consequence of iron deficiency. Lactoferrin improved serum iron, ferritin and hemoglobin more than ferrous sulfate across the pooled trials (Zhao et al., 2022), which makes unlocking women's everyday vitality a credible territory to build on.

The supply problem that precision fermentation solves

The main reason lactoferrin has not already displaced ferrous salts in the supplement aisle is availability. Bovine lactoferrin is extracted from cow's milk, where it is present at very low concentrations, and extraction at commercial scale is technically demanding and expensive. This supply constraint has historically limited the widespread use of lactoferrin and the expansion of the category.

Precision fermentation changes that equation. By programming microorganisms to produce specific proteins, precision fermentation enables reliable, commercial-scale production of lactoferrin that would be very difficult to achieve consistently through traditional dairy extraction methods. Vivitein™ LF is Vivici's fermentation-derived bovine lactoferrin and is designed to address exactly this constraint; making consistent, scalable supply a realistic proposition for health and wellness brands building lactoferrin-based products.

For innovation and marketing leaders, this is the part that matters. The clinical evidence for lactoferrin is not new. What has been missing is the ability to obtain it in the volumes, and at the consistency, that a national launch requires, and that is what has held the category back. Removing that constraint removes the supply risk and price volatility that have made lactoferrin difficult to build a category around.

The opportunity for health and wellness brands

Fatigue driven by iron deficiency in women is a large, real, and poorly served health need. The standard iron supplement category has a 40% tolerability problem that drives non-compliance and limits repeat purchases. Lactoferrin and its mechanisms are well characterized, and supports claims around iron regulation, gentle supplementation, unlocking iron and sustained energy that ferrous salts cannot credibly make.

The market opportunity spans capsules, tablets, gummies, functional powders and fortified foods. Vivitein™ LF is built to bring the published benefits of lactoferrin into formats where the iron and women's energy category has always fallen short. If your team is working on women's vitality, iron support, or energy innovation: the research base is there. The supply constraint has been addressed. The question now is what you build with it.

References

Abu Hashim, H., Foda, O., & Ghayaty, E. (2017). Lactoferrin or ferrous salts for iron deficiency anemia in pregnancy: A meta-analysis of randomized trials. European Journal of Obstetrics & Gynecology and Reproductive Biology, 219, 45–52. https://doi.org/10.1016/j.ejogrb.2017.10.003

Artym, J., Zimecki, M., & Kruzel, M. L. (2021). Lactoferrin for prevention and treatment of anemia and inflammation in pregnant women: A comprehensive review. Biomedicines, 9(8), 898. https://doi.org/10.3390/biomedicines9080898

Christofi, M.-D., Giannakou, K., Mpouzika, M., Merkouris, A., Vergoulidou-Stylianide, M., & Charalambous, A. (2024). The effectiveness of oral bovine lactoferrin compared to iron supplementation in patients with a low hemoglobin profile: A systematic review and meta-analysis of randomized clinical trials. BMC Nutrition, 10, Article 20. https://doi.org/10.1186/s40795-023-00818-6

Gawai, S., Fonseca, M., & Kapote, D. (2020). A randomized controlled trial on lactoferrin versus ferrous sulphate for the treatment of mild to moderate iron deficiency anaemia in pregnancy. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 9 (2), 562–566. https://doi.org/10.18203/2320-1770.ijrcog20200336

Koikawa, N., Nagaoka, I., Yamaguchi, M., Hamano, H., Yamauchi, K., & Sawaki, K. (2008). Preventive effect of lactoferrin intake on anemia in female long distance runners. Bioscience, Biotechnology, and Biochemistry, 72(4), 931–935. https://doi.org/10.1271/bbb.70383

Nappi, C., Tommaselli, G. A., Morra, I., Massaro, M., Formisano, C., & Di Carlo, C. (2009). Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: A prospective controlled randomized study. Acta Obstetricia et Gynecologica Scandinavica, 88(9), 1031–1035. https://doi.org/10.1080/00016340903117994

Tolkien, Z., Stecher, L., Mander, A. P., Pereira, D. I. A., & Powell, J. J. (2015). Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLOS ONE, 10(2), Article e0117383. https://doi.org/10.1371/journal.pone.0117383

World Health Organization. (2023, August 9). Daily iron supplementation in adult women and adolescent girls. e-Library of Evidence for Nutrition Actions (eLENA). https://www.who.int/tools/elena/interventions/daily-iron-women

Zhao, X., Zhang, X., Xu, T., Luo, J., Luo, Y., & An, P. (2022). Comparative effects between oral lactoferrin and ferrous sulfate supplementation on iron-deficiency anemia: A comprehensive review and meta-analysis of clinical trials. Nutrients, 14(3), 543. https://doi.org/10.3390/nu14030543